EADV 2024 | HANSOH PHARMA RELEASED THE PHASE II CLINICAL STUDY DATA OF HS-10374，IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
The 33rd Annual Congress of the European Academy of Dermatology and Venereology (EADV 2024) was held in Amsterdam from September 25 to 28, 2024. The Phase II clinical trial data for Hansoh Pharma 's HS-10374 on plaque psoriasis were presented at the congress in the form of an oral presentation.
The EADV Congress is Europe’s largest international meeting focused on dermatology and venereology, providing a platform for researchers, clinicians, and industry professionals to exchange knowledge, network, and present their latest research findings.
HS-10374 is a novel, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor developed by Hansoh Pharma. As TYK2 is essential for signaling of interleukin (IL)-12 and IL-23, which are key cytokines involved in psoriasis pathogenesis, HS-10374 was expected to offer therapeutic benefit in the treatment of psoriasis.
The recently published clinical trial results of HS-10374 showed significant clinical efficacy versus PBO in terms of PASI 75 response rate and sPGA 0/1 response rate with oral doses of ≥6 mg in patients with moderate-to-severe plaque psoriasis. The overall safety profile was similar to other TYK2 inhibitors but showed less risk of skin toxicity. Trials with a longer treatment duration and larger populations are required to further confirm the efficacy and safety of HS-10374 in such patients.
Study profile
Title: Efficacy and Safety of HS-10374 in Patients with Moderate-to-Severe Plaque Psoriasis: Results from A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Trial
Format: Oral presentation
Session code and title: D3T01.4 Late breaking news
Presentation time: September 27th, 2024, 16:00 (CEST)/22:00 (CST)
Abstract N°: 7722
Corresponding author: Jinhua Xu，Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
First author: Ling Han，Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Presenter: Yan Zhou，Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China.
Methods:
In this phase 2, randomized, double-blind, placebo-controlled trial (NCT06077331), 125 patients with moderate-to-severe plaque psoriasis were randomized 1:1:1 to receive HS-10374 6 mg, 12 mg or placebo (PBO) orally once daily (QD). The treatment period was 12 weeks, followed by a 4-week follow-up period for safety monitoring.
Results:
Efficacy (data at Week 12): The primary endpoint was met, with a significantly greater proportion of patients in HS-10374 6 mg and 12 mg groups achieving PASI 75 responses compared with PBO (PBO: 7.5%; HS-10374 6 mg: 28.6%, P=0.013; HS-10374 12 mg: 72.1%, P<0.001). Significantly greater proportion of patients in HS-10374 6 mg and 12 mg groups achieved sPGA 0/1 responses compared with PBO as well (PBO: 10.0%; HS-10374 6 mg: 33.3%, P<0.05; HS-10374 12 mg: 65.1%, P<0.001).
Safety: AE rates of HS-10374 groups were slightly higher than PBO group (PBO: 70.0%; HS-10374 6 mg: 76.2%, HS-10374 12 mg: 88.4%), while rates of treatment-related AEs (TRAEs), serious AEs (SAEs), and AEs leading to discontinuation of trial regimen were comparable across the three treatment groups, and the only patient with treatment-related SAE was from PBO group. The overall safety profile of HS-10374 was similar to other TYK2 inhibitors. In contrast to the relative higher incidence of skin-related adverse events for some other TYK2 inhibitors, AEs under “skin and subcutaneous disorders” in this study were more commonly reported in PBO group. Treatment with HS-10374 did not result in significant changes from baseline in mean values of laboratory parameters.
Conclusion:
Based on these Phase 2 results, Hansoh will initiate a Phase 3 study of HS-10374 in moderate-to-severe plaque psoriasis this year to further confirm the efficacy and safety of HS-10374.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
